Phase 3 N=322 Clinical Trial in Females With Female Pattern Hair Loss
Alopecia
Primary: Target Area Hair Count (TAHC) — 167.3; 169.7; 192.8; 194.4 hairs per centimeter squared — p=0.9170
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=312 Compare the Efficacy of Cinacalcet vs Traditional Vitamin D for Secondary Hyperparathyroidism (SHPT) Among Subjects Undergoing Hemodialysis
Hyperparathyroidism, Secondary
Primary: Percent Change From Baseline in Mean PTH During Efficacy Assessment Phase (EAP) — -7; -12.1 Percent change — p=0.346
Phase 1 N=89 Assessment of Arachidonic Acid Supplementation in Infant Formula on the Immune Response of Infants
Focus: Nutritional Requirements for Infants
Primary: Number of Antigen-presenting B Cells — 21.9; 22.8; 25.1 percentage of CD20+ B cells
Phase 3 N=638 Long-Term Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Pain
Chronic Pain
Primary: Mean Change in Average Daily Pain — 0.921 units on a scale
N/A N=100 Risperidone or Cognitive-Behavioral Therapy for Improving Medication Treatment for Obsessive-compulsive Disorder
Obsessive-Compulsive Disorder
Primary: Score on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) — 26.1; 27.2; 25.9; 22.6 units on a scale
Phase 3 N=60 Subjects' Satisfaction on Pan Facial Aesthetic Enhancement After Treatment With Azzalure® and the Restylane® Range
Aging
Primary: Subject Satisfaction for the Full Face — 92.9; 7.1 percentage of total subjects
Phase 2 N=230 A Placebo-Controlled Study for SPM 962 in Restless Legs Syndrome (RLS) Patients
Idiopathic Restless Legs Syndrome
Primary: Change of International Restless Legs Syndrome Study Group Rating Scale (IRLS) Score From the Baseline to the End of Titration/Maintenance Period — -9.8; -10.7; -14.4…
N/A N=50 The Clinical Utility of Thrombelastography in Guiding Prophylaxis of Venous Thromboembolism Following Trauma
Venous Thromboembolism
Primary: Hypercoagulability — 16; 18 participants
Phase 3 N=274 Study of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV™) Compared to CD.JEVAX™ in Toddlers
Japanese Encephalitis · Japanese Encephalitis Virus Disease
Primary: Percentage of Participants With Seroconversion to Japanese Encephalitis Chimeric Virus Following Vaccination With Either IMOJEV™ or CD.JEVAX™ Japanese Encephalitis…
Phase 2 N=17 This Study is Designed to Evaluate PD/PK and Safety of Replagal Manufactured by Two Different Processes.
Fabry Disease
Primary: Change From Baseline to Week 16 (EOS) in Urine Gb3 Levels — -28.68 (nmol/g creatinine)
N/A N=81 Continued Access Protocol
Atrial Fibrillation
Primary: Cryoablation Procedure Events (CPEs) — 1; 0; 0; 0 Participants
Phase 2 N=40 Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma
Multiple Myeloma
Primary: Maximum Tolerated Dose (MTD) — 20 mg LBH589
Phase 3 N=52 Highdose Nicotine Patch Therapy for Smokeless Tobacco Use
Smokeless Tobacco Use
Primary: End of Treatment (Week 8) Point Prevalence Abstinence — 11; 6 participants — p=0.05
N/A N=91 Methemoglobin Levels in Generally Anesthetized Pediatric Dental Patients Receiving Local Anesthetics
Methemoglobinemia
Primary: Peak Methemoglobin Blood Levels — 3.55; 1.63; 1.60 percentage of methemoglobin in blood — p=<.001
Phase 2 N=57 Vitamin D3 in Systemic Lupus Erythematosus
Systemic Lupus Erythematosus · SLE · Lupus
Primary: Percent of Participants With an IFN Alpha Signature Response at Week 12 — 36.8; 23.5; 27.8; 25.7 Percent of participants — p=0.53